Patents by Inventor Soren Christensen

Soren Christensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies specific for hyperphosphorylated tau and methods of use thereof
    Patent number: 11739140
    Abstract: The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: August 29, 2023
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Lars Østergaard Pedersen, Justus Claus Alfred Daechsel, Ayodeji Abdur-rasheed Asuni, Nina Helen Rosenqvist, Christiane Volbracht, Lone Helboe, Anders Brandt Elvang, Florence Sotty, Søren Christensen, Jeffrey B. Stavenhagen
  • AGENT, USES AND METHODS FOR TREATMENT
    Publication number: 20230159643
    Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: November 18, 2022
    Publication date: May 25, 2023
    Applicant: H. Lundbeck A/S
    Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Soren Christensen, Jan Egebjerg, Amout Gerritsen, Edward van den Brink, Paul Parren, Rob de Jong
  • Agent, uses and methods for treatment
    Patent number: 11548950
    Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful correcting a deficient level progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: January 10, 2023
    Assignee: H. Lundbeck A/S
    Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Arnout Gerritsen, Edward van den Brink, Paul Parren, Rob de Jong
  • BIOPSY APPARATUS HAVING A PIERCING MODULE
    Publication number: 20220387006
    Abstract: A biopsy apparatus includes a piercing module having a probe drive slider coupled to a probe carrier body of a biopsy probe assembly, and has a primed position and a fired position. A nut housing has a home position and an extended position. A drive spindle is drivably coupled to a motor driveshaft, and is coupled to the nut housing. A firing spring is interposed between a motor housing and the probe drive slider. A release arm is pivotably coupled to a piercing module frame. When the probe drive slider is in the primed position and the release arm is in a latch position, the release arm is positioned to engage the probe drive slider to hold the probe drive slider in the primed position. A release slider releases the release arm from the latch position when the nut housing is moved from the home position to the extended position.
    Type: Application
    Filed: November 19, 2020
    Publication date: December 8, 2022
    Applicant: Bard Peripheral Vascular, Inc.
    Inventors: Angela K. Jensen, Soren F. Orts, Soren Christensen
  • ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF
    Publication number: 20220177557
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PH F) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Application
    Filed: August 11, 2021
    Publication date: June 9, 2022
    Applicant: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Alfred Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • AGENTS, USES AND METHODS FOR TREATMENT
    Publication number: 20210292414
    Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders such as Alzheimers disease (AD).
    Type: Application
    Filed: December 11, 2020
    Publication date: September 23, 2021
    Applicant: H. Lundbeck A/S
    Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Tina Stummann, Arnout Gerritsen, Edward van den Brink, Paul Parren, Esben Trabjerg, Kasper Dyrberg Rand
  • Antibodies specific for hyperphosphorylated tau and methods of use thereof
    Patent number: 11111290
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: September 7, 2021
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Alfred Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • AGENT, USES AND METHODS FOR TREATMENT
    Publication number: 20210269524
    Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful correcting a deficient level progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: November 13, 2020
    Publication date: September 2, 2021
    Applicant: H. Lundbeck A/S
    Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Arnout Gerritsen, Edward van den Brink, Paul Parren, Rob de Jong
  • ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF
    Publication number: 20210206843
    Abstract: The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.
    Type: Application
    Filed: January 8, 2021
    Publication date: July 8, 2021
    Applicant: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Lars Østergaard Pedersen, Justus Claus Alfred Daechsel, Ayodeji Abdur-rasheed Asuni, Nina Helen Rosenqvist, Christiane Volbracht, Lone Helboe, Anders Brandt, Florence Sotty, Søren Christensen, Jeffrey B. Stavenhagen
  • Antibodies specific for hyperphosphorylated tau and methods of use thereof
    Patent number: 10934348
    Abstract: The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: March 2, 2021
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Lars Østergaard Pedersen, Justus Claus Alfred Daechsel, Ayodeji Abdur-rasheed Asuni, Nina Helen Rosenqvist, Christiane Volbracht, Lone Helboe, Anders Brandt Elvang, Florence Sotty, Søren Christensen, Jeffrey B. Stavenhagen
  • Agents, uses and methods for treatment
    Patent number: 10894833
    Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders such as Alzheimers disease (AD).
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: January 19, 2021
    Assignee: H. Lundbeck A/S
    Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Tina Stummann, Arnout Gerritsen, Edward van den Brink, Paul Parren
  • Agent, uses and methods for treatment
    Patent number: 10889650
    Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: January 12, 2021
    Assignee: H. Lundbeck A/S
    Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Arnout Gerritsen, Edward van den Brink, Paul Parren, Rob de Jong
  • STORAGE AND COLLECTION SYSTEMS AND METHODS FOR USE
    Publication number: 20200191580
    Abstract: Systems and methods for managing the collection of contents from geographically distributed containers are disclosed herein. The systems can have a sensor in the container in data communication with a server system. The sensor can send data regarding the volume of contents in the container to the server system. The server system can then create routing information for a fleet of vehicles to empty the containers based on which containers are full enough for immediate collection, other predictive data for less full containers, and traffic and other routing factors for the vehicles. The server system can then transmit the routing information to the vehicles, track the vehicles, and prepare reports.
    Type: Application
    Filed: February 25, 2020
    Publication date: June 18, 2020
    Applicant: Nordsense, Inc.
    Inventors: Søren CHRISTENSEN, Manuel MAESTRINI
  • ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF
    Publication number: 20200190178
    Abstract: The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.
    Type: Application
    Filed: December 20, 2019
    Publication date: June 18, 2020
    Inventors: Jan Torleif Pedersen, Lars Østergaard Pedersen, Justus Claus Alfred Daechsel, Ayodeji Abdur-rasheed Asuni, Nina Helen Rosenqvist, Christiane Volbracht, Lone Helboe, Anders Brandt Elvang, Florence Sotty, Søren Christensen, Jeffrey B. Stavenhagen
  • AGENT, USES AND METHODS FOR TREATMENT
    Publication number: 20200190188
    Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: July 24, 2019
    Publication date: June 18, 2020
    Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Arnout Gerritsen, Edward van den Brink, Paul Parren, Rob de Jong
  • Antibodies specific for hyperphosphorylated tau and methods of use thereof
    Patent number: 10647762
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: May 12, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF
    Publication number: 20200109192
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PH F) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Application
    Filed: September 27, 2019
    Publication date: April 9, 2020
    Inventors: Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Alfred Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • Antibodies specific for hyperphosphorylated tau and methods of use thereof
    Patent number: 10562962
    Abstract: The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: February 18, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Lars Østergaard Pedersen, Justus Claus Daechsel, Ayodeji Abdur-rasheed Asuni, Nina Helen Rosenqvist, Christiane Volbracht, Lone Helboe, Anders Brandt Elvang, Florence Sotty, Søren Christensen, Jeffrey B. Stavenhagen
  • IMMUNOLOGICAL TREATMENT OF CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS AND LEUKOENCEPHALOPATHY
    Publication number: 20200048342
    Abstract: The present invention relates to an anti-Notch 3 antibody therapy useful for treatment of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. In particular, the invention relates to an anti-Notch3 antibody or a fragment thereof having a 2 fold, 4 fold or 10 fold higher affinity to Notch 3 than to Notch 1 or Notch 2 for use in therapy.
    Type: Application
    Filed: July 23, 2019
    Publication date: February 13, 2020
    Inventors: Anne Joutel, Søren Christensen, Thorleif Jan Pedersen
  • Antibodies specific for hyperphosphorylated tau and methods of use thereof
    Patent number: 10487142
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: November 26, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe